Advances in S-Triazine-Based Therapeutics: From Antimicrobials to Neurodegenerative Disease Modulators

Dear Colleagues,

1,3,5-Triazine, known as s-triazine, is one of the oldest heterocyclic compounds available, and due to its low cost and high availability, it has continually attracted the attention of scientists who aim to synthesize and investigate the activity of its new derivatives.

Nucleophilic substitution in the s-triazine ring is favored over electrophilic substitution due to its lower basicity and much weaker resonance energy than that of benzene. Thus, a number of heterocyclic compounds with a symmetric s-triazine core have been obtained, which represent an interesting class of compounds with a wide spectrum of biological properties. Among them, triazine is not only a core, but also a factor that increases the kinetic potential of the whole derivatives. In medicinal chemistry, the most interesting derivatives to date have been those with anticancer, antiviral, antimicrobial, or antimalarial activity. Recently, however, derivatives with activity against agents in other clinical problems, such as neurodegenerative diseases, have also been obtained.

This Special Issue focuses on recent developments in the design, synthesis, and activity testing of new s-triazine derivatives, as well as new molecular targets for these compounds. Literature reviews summarizing knowledge from various studies on s-triazine and its derivatives are also welcome for publication.

Dr. Danuta Drozdowska
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.